Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Background Passive immunization with plasma collected from convalescent patients has
been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are …

As the COVID-19 pandemic has evolved during the past years, interactions between human
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …

Abstract WHO-defined SARS-CoV-2 variants of concern (VOC) drive therapeutics and
vaccine development. The Omicron VOC is dominating the arena since November 2021, but …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the devastating global COVID-19 pandemic announced by WHO in March 2020. Through …

Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …

Immunocompromised individuals and particularly those with hematologic malignancies are
at increased risk for SARS-CoV-2-associated morbidity and mortality due to immunologic …

Monkeypox, a zoonosis caused by the orthopox monkeypox virus (MPXV) that is endemic to
Central and West Africa, was previously linked to sporadic outbreaks and rare, travel …

Background It is unknown whether convalescent immunoglobulins (cIgGs) are better than
convalescent plasma (CP) for patients with coronavirus 2019 (COVID-19). Methods In this …